Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Developments Infections and Infectious Diseases Phase I
Spain 
Details:
GIGA-2050 is comprised of more than 12,000 antibodies demonstrating strong neutralizing activity against natural SARS CoV-2 variants in laboratory studies, including the delta variant and other variants that have emerged globally since the beginning of the pandemic.
Lead Product(s): GIGA-2050
Therapeutic Area: Infections and Infectious Diseases Product Name: GIGA-2050
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2021
Details:
PharmaMar’s cancer drug Aplidin (plitidepsin) has demonstrated ‘potent preclinical efficacy’ against SARS-CoV-2, the virus which causes COVID-19. Aplidin inhibits the eEF1A protein, which is associated with the SARS-CoV-2 virus.
Lead Product(s): Plitidepsin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Apices Soluciones
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2021
Details:
There was a substantial reduction in viral load and the C-reactive protein (CRP) in patients, and that 80.7% of patients had been discharged before the 15th day of hospitalisation, and 38.2% before the eighth day.
Lead Product(s): Plitidepsin
Therapeutic Area: Infections and Infectious Diseases Product Name: Aplidin
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2020
